Zevra Therapeutics Inc (FRA:1GDA)
€ 4.22 -0.22 (-4.95%) Market Cap: 177.71 Mil Enterprise Value: 169.84 Mil PE Ratio: 0 PB Ratio: 3.90 GF Score: 50/100

Q1 2023 Zevra Therapeutics Inc Earnings Call Transcript

May 15, 2023 / 08:30PM GMT
Release Date Price: €3.84 (-0.52%)
Operator

Good afternoon, and welcome to the Zevra Therapeutics First Quarter 2023 Corporate and Financial Results Conference Call. (Operator Instructions) Please be advised that this -- today's call is being recorded.

I would now like to turn the call over to Nichol Ochsner, Zevra Therapeutics' Vice President, Investor Relations and Corporate Communications. Please go ahead, ma'am.

Nichol L. Ochsner
Zevra Therapeutics, Inc. - VP of IR & Corporate Communications

Good afternoon. Thank you for joining us today to review updates related to Zevra's first quarter 2023 clinical, operational progress and financial results. A few housekeeping items before we start. I invite you to view the webcast slides and the press release, both of which were issued this afternoon and can be found in the Investors section of our website.

During today's call, we will be making statements -- several forward-looking statements. These forward-looking statements include, but are not limited to, the clinical, regulatory and commercial path for arimoclomol, AZSTARYS; revenue

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot